| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
JPI-547 targets PARP1/2 and tankyrase1/2. It inhibits PARP1/2, preventing PARP-mediated DNA repair, and inhibits tankyrase1/2, disrupting the Wnt/β-catenin pathway. This dual inhibition leads to accumulation of DNA damage, G2/M phase arrest, and apoptosis. It traps PARP1 on chromatin and disrupts poly-ADP-ribosylation.
|
|---|---|
| ln Vitro |
In vitro, JPI-547 inhibits tankyrases 1, tankyrases 2, and PARP 1 with IC50s of 5, 1, and 2 nM, respectively. It efficiently traps PARP1 on chromatin, disrupts poly-ADP-ribosylation, induces G2/M phase arrest, and triggers apoptosis in PDAC cells. It has antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction.
|
| ln Vivo |
In vivo, JPI-547 has demonstrated antitumor activity in animal models of pancreatic cancer. It is orally active and effectively inhibits tumor growth. It is being evaluated in clinical trials for advanced solid tumors. It is not approved for therapeutic use.
|
| Enzyme Assay |
For non-cell enzyme assays, recombinant PARP1 or tankyrase is incubated with JPI-547 and a biotinylated NAD+ substrate. Enzyme activity is measured by detecting ADP-ribose polymers using chemiluminescence. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In cell assays, PDAC cell lines are treated with serial dilutions of JPI-547. Cell viability is measured by MTT or CellTiter-Glo. PARP1 trapping and poly-ADP-ribosylation are measured by Western blot. Apoptosis is assessed by Annexin V staining.
|
| Animal Protocol |
In vivo animal protocols use mice bearing pancreatic cancer xenografts. JPI-547 HCl is dissolved in DMSO/PEG/saline and administered orally. Tumor volume is measured twice weekly. Pharmacokinetic parameters are determined by LC-MS.
|
| Exact Mass |
472.155
|
|---|---|
| CAS # |
2055357-65-6
|
| Related CAS # |
2055357-64-5;2055357-65-6 (HCl);
|
| PubChem CID |
171612926
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
84.3
|
| Hydrogen Bond Donor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
733
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CC2=C(C3=C(C=C(C=C3)CN4CCN(CC4)C5=NC=C(C=C5)C#N)NC2=O)NC1.Cl.Cl
|
| InChi Key |
YXISBTCLOKWYHB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H24N6O.2ClH/c24-13-17-4-6-21(26-14-17)29-10-8-28(9-11-29)15-16-3-5-18-20(12-16)27-23(30)19-2-1-7-25-22(18)19;;/h3-6,12,14,25H,1-2,7-11,15H2,(H,27,30);2*1H
|
| Chemical Name |
6-[4-[(5-oxo-2,3,4,6-tetrahydro-1H-benzo[h][1,6]naphthyridin-8-yl)methyl]piperazin-1-yl]pyridine-3-carbonitrile;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.